A reason to celebrate  by O'Reilly, Richard J.
Biology of Blood and Marrow Transplantation 7:305 (2001) 
9 2001 American Society for Blood and Marrow Transplantation 
Letter From the President 
A Reason To Celebrate 
If the medical community held a party to celebrate ach 
milestone, there would be every reason for this issue of 
I?BMT to arrive decorated with balloons and streamers. 
On the pages of this issue is an important report, an evi- 
dence-based review of hematopoietic stem cell transplanta- 
tion for the treatment of large cell B-cell non-Hodgkin's 
lymphoma. This is the first in a series of evidence-based 
reviews commissioned by ASBMT on the effectiveness of 
autologous and allogeneic stem cell transplantation for spe- 
cific diseases. 
A panel of experts from the transplantation community 
and other medical specialties, third-party payers and patient 
advocates labored for more than a year to produce the 
report, and they deserve our gratitude for an outstanding 
effort and final report. 
COALITION OF STAKEHOLDERS 
The ASBMT officers and Board members et the stage 
for the review in 1999 when they launched our society's 
Managed Care Initiative, a public affairs program to address 
the issue of patient reimbursement for transplantation i  
cases where BMT efficacy is widely recognized. The strat- 
egy of the program has been to bring together a coalition of 
experts representing the breadth of disciplines that con- 
tribute to the management of each disease to evaluate the 
role of BMT, disseminate those evaluations and, when 
appropriate, advocate on behalf of BMT patients. 
It was agreed early on that a series of evidence-based 
reviews was needed to document the role of BMT to those 
who decide or influence treatment reimbursement d cisions. 
To keep the science of the reviews at arm's length from the 
politics of the society, the Board of Directors appointed an 
independent Steering Committee for the evidence-based 
reviews. It has been the committee's responsibility, in turn, 
to appoint an expert panel for each review. 
In its review and analysis of the literature pertaining to 
the treatment of NHL, the Expert Panel was compelled to 
exclude several studies because of flaws in study design, exe- 
cution, or analysis. This prompted the Steering Committee 
to prepare an editorial that accompanies the evidence-based 
review in this BBMT issue. The editorial speaks to specific 
problems that were found, and it offers recommendations for
investigators on the design and reporting of future studies. 
The names of the volunteers who contributed exper- 
tise and untold hours to this program are on the articles, 
so I won't take additional space here to name them, other 
than to applaud the chair of the Steering Committee, Roy 
Jones, and the chair of the Expert Panel, Steven Wolff. 
Special thanks also go to Theresa  Hahn and Phil ip 
McCarthy of Roswell Park Cancer Institute for their 
central role in the research and preparation of the review. 
We also must express gratitude to a number of com- 
panies that provided unrestricted educational grants to 
underwrite the costs of this very expensive ongoing pro- 
gram: Amgen, Aventis, Fujisawa Healthcare,  Merck, 
Nexell Therapeutics and SangStat. These companies are 
supporting our efforts for the long haul because they 
understand how important his initiative is to us and to 
the patients we serve. 
THE NEXT STEPS 
As the Steering Committee and a new expert panel 
work toward completion of the next review--this one 
evaluating the role of BMT in multiple myeloma-- i t  is 
important hat we now turn our attention to how we put 
these valuable tools to good use. Another group within the 
society is managing our communications with managed 
care, legislative and regulatory agencies, the consumer 
media and the general public. Reprints of the articles will 
be widely circulated. 
However, the review is there for you to use, too. This 
and furore reviews will be posted on the ASBMT Web site 
and you can photocopy the review in this issue of BBMT to 
provide to referring physicians, use as documentation i
your relations with managed care and insurance companies, 
and use as a foundation for further clinical research. 
The publication of this review represents the end of a 
beginning, the first step in a demanding but exciting jour- 
ney. We believe it reflects the Society's commitment to 
critical analysis and the scientific discipline of clinical 
research. It also provides a useful benchmark for assessing 
progress and defining goals for the future. That's plenty 
reason to celebrate. 
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